Abstract
Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Current Medicinal Chemistry
Title: Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action
Volume: 11 Issue: 1
Author(s): Peter Matyus, Ildiko Varga, Tivadar Rettegi, Antal Simay, Nikolett Kallay, Laszlo Karolyhazy, Akos Kocsis, Andras Varro, Istvan Penzes and Julius Gy. Papp
Affiliation:
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Abstract: Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Export Options
About this article
Cite this article as:
Matyus Peter, Varga Ildiko, Rettegi Tivadar, Simay Antal, Kallay Nikolett, Karolyhazy Laszlo, Kocsis Akos, Varro Andras, Penzes Istvan and Papp Gy. Julius, Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action, Current Medicinal Chemistry 2004; 11 (1) . https://dx.doi.org/10.2174/0929867043456232
DOI https://dx.doi.org/10.2174/0929867043456232 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity
Current Topics in Medicinal Chemistry Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Neuroimmune Activation in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Application of Proteomics in Cardiovascular Research
Current Proteomics Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Acute Actions of Natriuretic Peptides in Coronary Vasculature and Ischaemic Myocardium
Current Pharmaceutical Design Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones
Recent Patents on Anti-Infective Drug Discovery Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Ion Channels as Medicinal Targets of Biological Toxins: The Impact of Automated Patch-Clamp Electrophysiology
Current Topics in Medicinal Chemistry Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design The Role of Zebrafish in Chemical Genetics
Current Medicinal Chemistry